JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts JANX014 Phase 1 study continues enrolling...
Barchart Research What to Expect from JANX Earnings JANX Generated August 5, 2026 Current Price $16.00 EPS Estimate $$-0.26 Consensus Rating Moderate Buy Average Move 2.88% Janux Therapeutics: Whether...
JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation...
Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.24%. June E-mini S&P futures...
- JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development priority...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate...
Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed...
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated...